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Chapter 1
Introduction
Lipodystrophy
Lipodystrophy is a condition caused by fat deficiency where adipose cells
are destroyed or barely present (1). The disease exists in genetic and acquired
forms, the former being very rare. Congenital generalized lipodystrophy (the
Seip-Berardinelli syndrome) and the familial partial lipodystrophies (the Dunnigan
type, the Kobberling type and the mandibuloacral dysplasia type) are the genetic
forms. Acquired partial lipodystrophy (the Barraquer- Simons syndrome),
acquired generalized lipodystrophy (the Lawrence syndrome) and protease
inhibitors-induced lipodystrophy (HIV treatment) are the acquired forms. HIV
related lipodystrophies are observed in about 50% of HIV patients, being the
most common form of lipodystrophy (2).
There exist two methods through which dysfunctional adipose tissue may
play a role in metabolic disease: the first is the reduced capability to store
triglycerides which in turn leads to an increase in the levels of circulating fat as
well as the deposition of excess lipids in non-adipose tissues. The second is
anomalies in the production of hormones and adipokines. In lipodystrophic or
obesity-mediated metabolically ill patients, these two pathways typically occur
concurrently, rendering it hard to determine the mechanistic and/or pathogenic
determinants of these disorders (3).
These

patients

also

suffer

from

other

anomalies

including

hypertriglyceridemia along with insulin resistance and type II diabetes (4), which
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in turn lead to further complications: severe hypertriglyceridemia eventually
causes recurrent acute pancreatitis attacks, and severe hyperglycemia increases
the risk for diabetic nephropathy and retinopathy. They also develop
steatohepatitis which may lead to cirrhosis (5).
Treatment Modalities for Lipodystrophy
The major characteristics of lipodystrophy, insulin resistance and
hypertriglyceridemia are usually managed by multiple drugs including lipidlowering medications along with insulin therapy and/or oral hypoglycemics (5);
however, they have been so far resistant to treatment (6). Thiazolidinediones
have been shown to be an effective therapy, yet not the perfect one (7). Other
treatment modalities have also been attempted. For instance, Wanke et al
treated 10 HIV-induced lipodystrophy patients with Recombinant Human Growth
Hormone (rhGH) for 3 months and found that this short-term rhGH treatment was
an effective therapy for the body shape alterations that accompany the syndrome
(8).
Leptin replacement therapy, so far, seems to be the most effective therapy
for lipodystrophic patients. This was first demonstrated in 2002 by Oral et al in
studies where they administered recombinant leptin subcutaneously to nine
lipodystrophic patients over four months. This treatment resulted in an
improvement in glycemic control, a decrease in triglyceride levels and a reduction
in liver volume, as well as decreased food intake and resting energy expenditure
(5). Similarly, Simha et al found in 2003 that leptin replacement therapy reduced
intramyocellular and intrahepatic lipid content in three such patients (9). The
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reduced food intake, decreased energy expenditure and reduced liver volume in
response to leptin treatment were further demonstrated by Moran et al in 2004
(10). Javor et al tested the long-term efficacy of leptin treatment in 15
lipodystrophic patients for 12 months. They also found, in 2005, that leptin
administration led to marked improvements in glycemia, dyslipidemia and hepatic
steatosis (estimated by liver volume), announcing leptin as the first effective longterm treatment for severe lipodsytrophy (11). Ebihara et al confirmed in 2007 that
leptin administered to generalized lipodystrophy patients improves insulin
sensitivity as well as lipid metabolism (12).
What is Leptin?
Being a triglyceride storage depot and an endocrine tissue, white adipose
tissue plays an important role in energy metabolism as well as lipid and glucose
homeostasis. The adipocytes from white adipose tissue produce hormones that
regulate food intake and metabolism, mainly leptin and adiponectin (13). The
adipocyte-derived hormone leptin was discovered in 1994 by Zhang et al as a
protein product of a defective gene in the ob/ob mouse (14). Leptin plays a major
role in food intake and energy expenditure regulation (15), as it is known to
reduce food intake and increase metabolism. Several studies have shown that its
administration to leptin-deficient and normal rodents results in patent reductions
in food intake, body weight and body fat. The obese population, on the other
hand, has elevated leptin and does not appear to benefit from leptin therapy, a
concept typically called “leptin resistance” (16).
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Leptin receptors, through which leptin regulates energy homeostasis, are
expressed in the hypothalamus (17) and many peripheral tissues (18). The levels
of regulation vary: Fatty acid oxidation (19) and glucose uptake in skeletal
muscle cells (20) are stimulated by leptin, whereas hepatic gluconeogenesis and
lipogenesis are inhibited by leptin (21, 22). Leptin reduces pancreatic B-cell
production of insulin (23) and also enhances insulin action (24), which is thought
to be controlled via a cascade of reactions (25). Leptin's effect on glucose and
lipid metabolism and insulin sensitivity appears to be mostly independent of its
regulation of food intake (26). However, various pathways are known to mediate
its metabolic effects. For instance, leptin represses the gene stearoyl-CoA
desaturase-1 (SCD-1) which plays a role in leptin-induced metabolic changes
(27). Leptin also plays a role in growth and reproduction (28), inflammation,
hematopoiesis (29) and immunity (28, 29).
Hyperleptinemia is commonly seen in obese patients revealing increased
adiposity and leptin resistance. This profile may contribute to the hypertension,
impaired glucose metabolism, and pro-atherogenic condition in obese and
metabolic syndrome patients (30).
Mouse Models of Lipodystrophy
Excess adiposity in obesity and lack of adipose tissue in lipodystrophy are
both often coupled with insulin resistance and related complications. Strangely
enough, lipodystrophy shares similar metabolic abnormalities with obesity. For
treating lipodystrophy-related metabolic disorders, leptin replacement therapy is
a successful approach, yet it does not appear promising in the treatment of
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complications associated with obesity (31). However, a well-controlled genetically
modified lipodystrophy mouse model can help unravel these mechanisms and
also find therapeutic targets for treating/preventing the metabolic syndrome/
metabolic abnormalities related to obesity (3). Mouse models of lipodystrophy are
very useful in the sense that they may help understand these mechanisms and
possibly uncover new pharmaceutical targets for managing metabolic disorders
associated with dysfunctional adipose tissue (31).
Inducible, late onset and early onset mouse models of lipodystrophy have
been developed. There are two known inducible models: 1- Fat apoptosis
through targeted activation of caspase 8 (FAT-ATTAC) mice that are transgenic
mice suffering from adipose tissue ablation resulting from treatment with a
chemical dimerizer (32); and 2- Protease inhibitor-induced lipodystrophic mice
(3).
There are two late onset models as well: 1- aP2-diphteria toxin A mice
which are born with a normal phenotype but develop adipose tissue atrophy at
five to six months of age (33); and 2- Ribosomal S6 kinase 2 knockout mice
which display partial fat loss, reduced leptin levels, insulin resistance and a
propensity for liver steatosis (34).
There exist eight known early onset models: 1- The aP2-SREBP-1c
mouse is a transgenic mouse model of lipodystrophy expressing an active form
of the SREBP-1c transcription factor in its adipose tissue, causing remarkably
reduced

body fat, hepatic steatosis, insulin

resistance, hyperglycemia,

hypertriglyceridemia and enlarged organs (35). 2- Mox2-Cre-floxed PPARγ
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knockout mice are PPARγ deficient mice that are lipodystrophic and insulin
resistant. Only a small percentage of these mice survive until adulthood (36). 3Adipose-specific PPARγ knockout mice have only a small amount of adipose
tissue with decreased adipokine concentration. In addition, the adipose tissue
they have appears prone to inflammation. These mice also have elevated blood
lipids and a propensity for hepatic steatosis and insulin resistance (37). 4PPARγ-2 knockout mice are more viable than the PPARγ knockout mice, but
also have markedly reduced adipose tissue and circulating adipokines (38). 5PPARγ hypomorphic mice are PPARγ-1 deficient due to an alteration in a
PPARγ-2-specific exon. These mice also have markedly reduced body fat (39).
6- PPARγ P465L mice were made to mimic human patients with the dominant
negative PPARγ P465L mutation who experience partial lipodystrophy, liver
steatosis, altered lipid metabolism, insulin resistance and hypertension (40). 7Fatty liver dystrophy mice are generated from a lipin1 gene mutation and are also
lipodystrophic (41). 8- Last but not least, the A-ZIP/F-1 mouse is a transgenic
mouse that lacks white adipose tissue for life via expressing the AZIP/F protein
(42).
The AZIP/F-1 Lipodystrophic Mouse
The AZIP/F-1 mouse was produced by adipose-selective expression of a
dominant-negative form of the transcription factor C/EBPα thus expressing the AZIP/F protein, under the control of the adipose-specific aP2 enhancer/promoter.
C/EBPα normally regulates adipocyte differentiation. A-ZIP/F prevents the DNA
binding of B-ZIP transcription factors of the C/EBP and Jun families. The mice
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therefore have little to no white adipose tissue throughout life and minimal
amounts of brown adipose tissue (42).
They firstly encounter delayed development that is then caught up by
week 12 when their body weight exceeds that of their non-transgenic littermates.
They are also characterized by reduced fertility. They have severe hepatic
steatosis as well as enlarged organs in general. They tend to develop type II
diabetes as they are hyperinsulinemic (50- to 400-fold) at 1 week of age and
hyperglycemic (3-fold) by 4 weeks of age. They have reduced leptin levels (20fold) and increased free fatty acids (2-fold) and triglycerides (3- to 5-fold). They
are finally polyphagic, polydipsic and polyuric (42).
The phenotype of AZIP/F-1 mice is very similar to that of patients with
severe lipoatrophic diabetes (1). The A-ZIP/F-1 phenotype therefore may serve
as a mouse model for human lipoatrophic diabetes (Seip-Berardinelli syndrome),
where the lack of fat contributes to a diabetic phenotype. According to the
authors, this model would help tackle the numerous drawbacks of lacking fat
throughout growth (42).
General Characteristics of Fatless Mice
The syndrome observed in lipoatrophic mice is markedly comparable to
that of lipoatrophic diabetes patients (43). AZIP mice, for instance, have nearly
no white adipose tissue, which results in hyperglycemia, insulin resistance,
hyperlipidemia, elevated liver triglycerides and hepatomegaly (44, 45). As it is
very well known, insulin resistance is the common precursor to type II diabetes
(46) and impairments in fat metabolism may promote insulin resistance (47, 48).
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Kim et al postulated that insulin resistance in the AZIP fatless mice may be
attributed to triglyceride accumulation in the liver and muscle due to the lack of
adipose tissue, which in turn alters insulin signaling and action (49).
Lipodystrophic mice, such as the AZIP/F-1 mice, are also hypertensive (50).
They have also been shown to have a high susceptibility to carcinogenesis that is
thought to be related to their insulin resistance and inflammatory state (51)
and/or the lack of adipose tissue (52).
Treatment of Lipodystrophy in Mice: Leptin Replacement Therapy
The metabolic abnormalities associated with lipoatrophy are clearly due to
the lack of white adipose tissue since surgical implantation of adipose tissue
reversed diabetes in lipoatrophic mice (53). Transplanting adipose tissue lacking
leptin into AZIP/F1 fatless mice, however, could not reverse the phenotype of
these mice. This evidence suggests that neither adiponectin deficiency nor the
lack of triglyceride accumulation into fat per se is responsible for the metabolic
abnormalities; it is rather leptin deficiency (54). Ebihara et al produced doubly
transgenic mice that are lipodystrophic but over-express leptin. The mice showed
hypophagia, improved insulin sensitivity and reduced hepatic steatosis in
comparison with pair-fed lipodystrophic mice suggesting that leptin (rather than
simply reduced food intake) exerted important metabolic benefits (55). In a study
conducted by Shimomura et al, leptin administration to lipodystrophic mice via
pumps achieving physiologic levels resulted in a noted improvement in
hypertriglyceridemia, insulin resistance, hyperglycemia and hepatic steatosis
(56). In another study, leptin reversed hyperglycemia and hyperinsulinemia in
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Irs1-/-,Irs3-/- double knockout lipoatrophic mice (57). Furthermore, leptin infused
centrally over 6 days to streptozotocin-induced diabetic rats (insulin-dependent
diabetes) promoted euglycemia, an effect that was not due to regulating food
intake or peripheral insulin levels, it was rather via regulating liver glucose
production, energy expenditure and peripheral glucose uptake (58). Leptin
replacement therapy also has other physiologic effects, beyond the control of
food intake, hypertriglyceridemia, hyperglycemia and liver steatosis. For
instance, Suganami et al found marked nephropathy in AZIP fatless mice which
was

reversed

by

leptin

administration

and

prevented

in

the

AZIP

transgenic/Leptin transgenic mouse that is fatless but produces leptin (59).
Vascular Function/Thrombosis
A procoagulant state has been observed in obese patients with insulin
resistance and in type 2 diabetes (60). In addition, inflammation resulting from
obesity may play a role in the development of atherosclerosis (61). Plaque
disruption in atherosclerosis triggers a thrombotic response characterized by the
formation of a thrombus in the atherosclerotic blood vessel thus potentially
exposing it to occlusive thrombosis and tissue (e.g. myocardial or cerebral)
infarction (62). Acute thrombosis, therefore, often mediates the clinical severity of
cardiovascular disease complications (63).
Many circulating substances altered in metabolic disease are thought to
influence thrombosis. Adiponectin, a protein produced by adipose cells, seems to
be reduced with the increase in adipose stores (64). Thrombus formation is
increased in adiponectin-deficient mice, a phenotype that was reversed when
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introducing adiponectin via an adenovirus, suggesting that adiponectin plays an
antithrombotic role (65). Acute high doses of TNF-α, the inflammatory mediator
secreted by inflammatory cells (66), were also shown to have an antithrombotic
effect in mice (67). PAI-1 has a detrimental effect on fibrinolysis being the
primary inhibitor of tissue plasminogen activator in the blood (68) and it plays a
prothrombotic role according to arterial thrombosis studies in mice (69). Another
factor that has been shown to play a role in thrombosis is the adipose-derived
hormone leptin.
Leptin and Thrombosis
Leptin appears to act as a prothrombotic factor. For example, leptin has
been shown to stimulate platelet aggregation via adenosine diphosphate (70).
The human platelet has a functional leptin receptor that was identified by
Maruyama et al in 2000. High concentrations of leptin promoted platelet
aggregation in vitro (71). Two human studies suggested that leptin is an
independent risk factor for coronary heart disease (72). Also, plasma leptin levels
were significantly associated with coronary artery calcification in a crosssectional study involving type 2 diabetes patients, after controlling for age,
gender and other factors such as adiposity and CRP. This finding led to the
suggestion that leptin may promote the proatherosclerotic risk posed by adiposity
(73).
Similar effects were also found in mice. Leptin, and especially exogenous
leptin, was shown to be positively correlated with vascular thrombosis in various
mouse models (30). Bodary et al found that daily leptin administration for 4
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weeks promoted thrombosis and atherosclerosis in apolipoprotein E- deficient
mice (74). The prothrombotic effect of leptin may be exerted via multiple sites
including leptin receptors on platelets, centrally-mediated sympathetic effects of
leptin (e.g. on blood pressure), as well as leptin receptor expression on
endothelial cells (69).
Consistent with the prothrombotic effect of leptin, the absence of leptin
has been shown to reduce thrombus formation. For example, thrombosis is
delayed and the thrombi formed are unstable in both leptin-deficient (ob/ob) and
leptin receptor-deficient (db/db) mice. Leptin administration increased platelet
aggregation thus enhancing the formation of and stabilizing thrombi in the former,
but not in the latter, suggesting a receptor-dependent effect of leptin on platelet
function and hemostasis (75). Mice with leptin receptor-deficient bone marrow
were protected from photochemical injury-induced arterial thrombosis. Leptin
administration has a prothrombotic effect following vascular injury in mice, an
effect that was absent in leptin receptor-deficient mice and seemed to be driven
by the interaction between leptin and the platelet leptin receptor (76). In addition,
inhibiting endogenous circulating leptin delayed arterial and venous thrombosis in
mice and rendered the formed thrombi unstable (77).
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Chapter 2
Objectives of this Study
Given the background information, the aims of this study were to 1)
Observe the thrombotic profiles of FVB/B6 Lipodystrophic mice; 2) Observe the
physiologic development and metabolic profiles of these mice via various
parameters; and 3) Examine the effect of exogenous leptin on these profiles,
while comparing to vehicle-treated and non-transgenic controls.
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Chapter 3
Materials and Methods
Animals
AZIP/F-1 transgenic (AZIP-TG) mice (strain name: FVB-Tg(Azip/F)1Vsn/J)
were obtained from The Jackson Laboratory (Bar Harbor, ME) and bred in house
to produce AZIP/F1 offspring. AZIP-TG mice express the AZIP/F1 gene under
the control of 7.6 kB of the adipocyte specific Fabp4 promoter and therefore have
nearly no white adipose tissue and a significantly reduced amount of brown
adipose tissue (42). AZIP-TG females are infertile or weakly fertile due to the
necessity of leptin and/or adipose tissue for lactation and fertility. Therefore, to
obtain a mix of transgenic and wild-type FVB/B6 F1 offspring, several steps were
followed: AZIP-WT females were crossed with AZIP-TG males. The offspring of
interest were the AZIP-TG males. C57BL/6J (B6) female mice were purchased
from Jackson Laboratories as well. The AZIP-TG males were crossed with B6
females (at sexual maturity, i.e. ~6 weeks of age) to obtain FVB/B6 F1 offspring.
B6 mice were chosen because they are the best characterized mouse strain for
metabolic phenotypes and are genetically not close to the FVB strain (78). In
addition, we had previously found FVB AZIP-TG mice to be sickly and poorly
viable for use in our photochemical injury model of arterial thrombosis. The FVB
x B6 offspring were found to be ideal for our studies as this breeding strategy had
reduced mortality among the AZIP-TG offspring.
The offspring of interest for the leptin pump study were the FVB/B6 males,
both transgenic and wild-type. Males were chosen rather than females because
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they are more biologically stable than the latter and do not encounter estrous
cycling, providing more controlled conditions for the experiment. Mice were eartagged and tailed (for genotyping purposes) and weaned at two and three weeks
of age, respectively.
All laboratory personnel had completed the required animal-handling
training offered by the Division of Laboratory Animal Resources (DLAR) under
the supervision of Wayne State University’s Animal Investigation Committee
(AIC) for proper handling of mice. The protocols used in the study were also
approved by the AIC prior to the initiation of the study. All mice were housed in
an animal room with ~53% relative humidity and a 22˚C ambient temperature.
Feeding
Breeders were fed the FormuLabDiet 5008 from LabDiet, which is a highenergy high-protein formula used in breeding colonies of rodents to maximize
reproduction. All other mice were fed Laboratory Rodent Diet 5001 from LabDiet,
which is a constant formula used to diminish nutritional variables in long-term
studies (PMI Nutrition International, Saint Louis, MO). All mice had access to
food and water ad libitum.
Genotyping
Genotypes of mice were determined via end-point Polymerase Chain
Reaction (PCR). Tail tip amputations were performed and DNA samples were
obtained from tail sections. Tail sections were digested using a solution that is
10% tail digestion buffer (50% 1M KCL, 20% 500mM Tris-HCL, 10% 10% Triton
X-100, 20% ultra pure water), 4% 10mg/ml Proteinase K enzyme and 86% ultra
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pure water. One hundred microliters of the solution was added to each tail
sample and the samples were incubated at 55oC overnight, mixed using the
Vortex Mixer (Fisher Scientific, Pittsburgh, PA) and spun at 16,100 x g for 10
minutes at room temperature in the Eppendorf Centrifuge 5415 D (Brinkman
Instruments, Westbury, NY). PCR reactions were performed using an Eppendorf
Mastercycler Gradient PCR machine (Brinkman Instruments) and utilizing four
“Azip” primers from Sigma-Genosys (Sigma-Aldrich, St. Louis, MO): Azip Mutant
1981 (sequence 5'-CTGTGCTGCAGACCACCATGG), Azip Mutant 1982 r
(sequence

5'-CCGCGAGGTCGTCCAGCCTCA),

Azip

Wild-Type

0042

(sequence 5'-CTAGGCCACAGAATTGAAAGATCT) and Azip Wild-Type 0043 r
(sequence 5'-GTAGGTGGAAATTCTAGCATCATCC), Go Taq Master Mix and
Nuclease-Free Water (Promega, Madison, WI). Two and a half percent agarose
gel was loaded with amplified product and Exactgene 100 BP DNA Ladder
(Fisher Scientific) and run on a Fisher Biotech Electrophoresis System/ Wide
Format Horizontal System FB-SB-2318 (Fisher Scientific). Gels were read via the
DigiDoc-It Imaging System (UVP Inc., Upland, CA).
Arterial Thrombosis
Blood flow was measured in 6 FVB/B6 (3 WT & 3 TG) male mice at 7-10
weeks of age. The Arterial Thrombosis Protocol described by Bodary et al (76)
was modified and followed: The procedure starts by anesthetizing the mice with
~50 mg/Kg body weight intraperitoneal sodium pentobarbital (Meds for Vets,
Sandy, UT) then securing them in the supine position and placing them under a
dissecting microscope (Nikon SMZ-645, Mager Scientific Inc, Dexter, MI). A

16
midline cervical incision is then applied in order to isolate the right common
carotid artery and apply a flow probe (model 0.5 PSB, Transonic Systems,
Ithaca, NY). A flow meter (Transonic model T402, Transonic Systems) is then
connected to the probe and blood flow is monitored via the computerized data
acquisition software DASYLab9 (Measurement Computing Corporation, Norton,
MA). The photochemical injury protocol described by Eitzman et al (79) was the
means through which carotid arterial injury and thrombosis were induced. The
photochemical used in this procedure is rose bengal (Fisher Scientific) which is
diluted in PBS to 10 mg/mL and then injected into the tail vein via a 27-gauge
Precision Guide needle with a 1-ml latex-free syringe (Becton Dickinson and Co,
Franklin Lakes, NJ) at a dose of 50 mg/kg. Rose Bengal is then activated by
exposing the mid common carotid artery to a 1.5-mW green light laser (540 nm,
Melles Griot, Carlsbad, CA) from a 6 cm distance. Blood flow in the artery is
observed from the time of the injection of rose bengal until the end of the
experiment. Two events would determine the end point for the experiment: the
cessation of blood flow in the carotid artery for one minute (read via the
DASYLab9 software) and the visualization of an occlusive thrombus at the injury
site via the dissecting microscope. The observer of both events would be blinded
to the mouse group.
Cell and Platelet Counts
Blood cell and platelet counts were obtained from seven FVB/B6 F1 males
(4 TG and 3 WT) at 13 weeks of age. Blood was obtained via a cardiac puncture
terminal bleed using a 25-gauge Precision Guide needle with a 3-mL latex-free
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syringe (Becton Dickinson and Co, Franklin Lakes, NJ) loaded with 3.2% NaCitrate (Sigma Inc., St. Louis, MO) where fresh circulating blood was obtained
from the heart (ratio of Na-Citrate to Blood was 1:10) and diluted with PBS to a
10,000 fold dilution. Ten microliters of diluted blood from each sample was
placed in the Hausser Levy Hemacytometer (VWR International Inc, Batavia, IL)
where platelets and total blood cells were counted under a Wilovert S Inverted
Microscope (Hund Wetzlar, Germany).
Euglobulin Clot Lysis Assay
A Euglobulin Assay was performed on blood samples obtained from five of
the mice (2 WT and 3 TG) mentioned above for the determination of fibrinolysis.
The protocol described by Smith et al (80) was followed with modifications. The
fresh citrated blood was spun and plasma was separated (described later) and
mixed with working acetic acid (1.3 ml per 75 ul plasma) in 1.5-2.0 ml
polypropylene tubes. The tubes were placed on ice for 10 minutes and spun at
2,000xg for 5 minutes at room temperature. Supernatants were discarded and
the tubes were inverted to drain for 5 minutes. The "euglobulin fraction" was
resuspended in 100 ul of a solution of 154 mM NaCl and 26 mM sodium borate,
stirred, warmed to 37oC for 90 seconds, re-stirred and warmed again to 37oC for
90 seconds. Samples were then pipetted into a pre-warmed 37oC 96-well
polystyrene flat-bottom microtiter plate, 90 ul per well. Each sample was pipetted
in duplicate and read on the ELx800 Absorbance Microplate Reader at 405 nm.
Ninety microliters of 0.025 M CaCl2 was added to one well of each sample while
the other served as an individual control. The plate was placed again in the
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microplate reader and absorbance was read at 405 nm every minute for the first
10 minutes and then once every 10 minutes for 3 hours. Maximum absorbance
was defined as the peak absorbance at 405 nm and lysis time was defined as the
time at which the curve, corrected for the individual blank, reaches an
absorbance of 0.05 or less.
CBC and PT Measures
Obtaining complete blood counts (CBC) and measuring clotting factors
were also steps followed towards trying to uncover the mechanism behind the
altered thrombotic profiles of AZIP-TG mice. Seven 28-week-old female FVB/B6
F1 mice (3 WT & 4 TG) were sent to the Division of Laboratory Animal
Resources (DLAR) clinical pathology lab (WSU) for CBC and measures of
prothrombin time (PT) from fresh blood. Each mouse was placed in a CO2
chamber for 30-45 seconds and blood was drawn via cardiac puncture. CBC
measures were obtained via Heska CBC-Diff Veterinary Hematology System
machine (Heska Corporation, Fort Collins, CO) and HeskaView Integrated
Software Product Version 2.0.2 data acquisition software (Heska Corporation).
PT was measured on the SCA2000 Veterinary Coagulation Analyzer
(Symbiotics, San Diego, CA) using IDEXX Coagulation Diagnostics PT
Cartridges (IDEXX Laboratories, Westbrook, ME).
a-PTT Measures
Seven female FVB/B6 F1 mice (4 TG, 3 WT) at 41-47 weeks of age were
sent to the DLAR clinical pathology lab to obtain levels of activated partial
thromboplastin time (a-PTT). The same bleeding protocol (as above) was
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followed. The a-PTT was also measured on the SCA2000 Veterinary Coagulation
Analyzer (Symbiotics) using IDEXX Coagulation Diagnostics a-PTT Cartridges
(IDEXX Laboratories).
Grouping for the Leptin Pump Study
To study the effect of leptin administration on thrombotic and metabolic
profiles of fatless mice, leptin was administered to the mice via osmotic pumps.
Sixteen FVB/B6 mice were divided into four groups as follows: 4 transgenic mice
that received leptin pumps (TG-Tx), 3 transgenic mice that received control
pumps (TG-C), 4 wild-type mice that received leptin pumps (WT-Tx) and 5 wildtype mice that received control pumps (WT-C). Reduced fertility in fatless mice
along with the difficulty of obtaining healthy male offspring limited the sample size
to 16 mice.
Leptin Pumps
Five µg leptin/day was administered to each mouse via an osmotic pump
over 12 days. Recombinant mouse leptin was obtained from the National
Hormone and Peptide Program (NHPP, Torrance, CA) and reconstituted with
PBS pH 7.4 by GIBCO (Invitrogen, Grand Island, NY) into a 0.83 ug/ul
concentration. ALZET Osmotic Pumps model 1002, Alza (DURECT Corporation,
Cupertino, CA) were used to deliver leptin at a rate of ~0.25 ul/hr. Pumps were
filled and primed following the company's instructions.
Surgical Procedure for Pump Implantation
The least invasive procedure, subcutaneous implantation, was used to
implant leptin and vehicle pumps in the mice at 8 weeks of age, under sterile
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conditions and following the company’s protocol. The mouse is first anesthetized
with inhaled Attane Isoflourane, USP (MINRAD, Inc., Bethlehem, PA). The lower
dorsal area is shaved, slightly posterior to the scapulae and a mid-scapular
horizontal incision is made in the skin (≈ 1 cm). Using a hemostat or forceps, a
pocket/path is created for the pump all the way along the spine, just before the
neck. The filled pump is then inserted in the pocket. Finally, the incision is sealed
with Oasis surgical adhesive (Oasis, Mettawa, IL) and the mouse is placed in a
separate cage. The pump contents are delivered into the local subcutaneous
space and absorbed by local capillaries resulting in systemic administration.
(Procedure modified from:

Alzet

technical

Information

manual,

Durect

Corporation, Cupertino, CA).
Blood Samples
Blood samples were obtained from mice one week prior to inserting
pumps, i.e. at ~7 weeks of age, via retro-orbital bleeds (orbital sinus
venipuncture), using Fisherbrand heparinized micro-hematocrit capillary tubes
cat # 22-362-566 (Fisher Scientific). Two bleeds were done at 7 weeks of age (23 days apart), so that adequate amounts of both plasma and serum could be
isolated to measure pre-pump parameters. On the 9th day of having the pump in,
during their 9th week of age, the mice were bled again for serum samples, to
measure effects of leptin treatment. All blood samples were obtained after a fivehour fast where the mice would have access to water only. For plasma samples,
blood was collected in 1.5 ml polypropylene tubes, spun immediately (or kept at
4oC until spinning) at 5,000 x g for 10 minutes at room temperature and plasma

21
was isolated and stored at -20oC. For serum samples, blood was collected in BD
Microtainer Serum Separators Ref 365959 (Becton Dickinson and Co), clotted for
two hours at room temperature, spun at 2,000 x g for 20 minutes at room
temperature and serum was isolated and stored at -20oC. These bleeding and
plasma/serum isolation procedures were followed in all other experiments
requiring blood samples, unless otherwise indicated.
Measuring Blood Glucose
On day 9 after pump placement, while bleeding for serum samples, fasting
blood glucose concentrations (mg/dl) were measured using the Ascensia Elite XL
glucometer (Bayer, Tarrytown, NY), to monitor differences between groups.
Monitoring Body Weight Change
During leptin pump experiments, parameters that were to be measured
daily were body weight and food intake. The mice were weighed at 10:00 am
everyday throughout the study using the Adventurer-Pro digital scale (Ohaus
Corporation, Pine Brook, NJ), to monitor weight change in response to leptin
treatment. Food remaining in the cage was weighed daily during the first week of
the experiment and food intake was estimated by subtraction. However, the
measurement was discontinued because food was being chewed but not
consumed, making the results very inaccurate.
Arterial Thrombosis (leptin pump study)
Blood flow was monitored on the twelfth day following pump placement, at
10 weeks of age, following the protocol previously described. The maximum
duration allowed for observing blood flow was 150 minutes in the FVB/B6 leptin
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pump experiment. Again, the observer was blinded to the mouse group
(treatment vs control, transgenic vs wild-type).
Tissue Harvesting
The above arterial thrombosis procedure is a non-survival protocol. After
disconnecting the mice from the flow probe, while they were still under the effect
of anesthesia, they were euthanized via a cardiac puncture terminal bleed for
plasma isolation and they were then dissected to harvest organs. The liver was
the primary organ of interest. Tissues were weighed while fresh and sections
were consistently removed and frozen. Kidneys, hearts, lungs, spleens and fat
pads (in WT mice) were also isolated and weighed. All isolated tissue/organ
samples were weighed using the Mettler Toledo digital scale Model XS104
(Mettler-Toledo, Columbus, OH) and stored in 1.5-2 ml tubes at -20oC. Blood
obtained from the terminal bleed was spun for plasma isolation, following the
same isolation technique used in previous bleeds.
Liver Homogenization
Frozen liver tissue was thawed and homogenized in order to be used in
assays to measure parameters of interest. Fifty milligrams of each liver sample
was homogenized in a BD Falcon Polypropylene Round Bottom Tube (Becton
Dickinson and Co) in 2 ml of lysis buffer (150 mM NaCl, 0.1% Triton X-100, 10
mM Tris) using a Model Pro200 Double-Insulated Homogenizer (PRO Scientific,
Oxford, CT). The resulting 5-fold diluted livers were spun and supernatants were
used in assorted assays as described.
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Measuring Leptin Levels
Leptin levels were measured in serum samples of mice pre and post pump
treatment, via a leptin ELISA. The Mouse Leptin ELISA Kit Catalog # 90030
(Crystal Chem, Downers Grove, IL) was used with provided standards and
controls.
Measuring Insulin Levels
To test the effect of leptin administration on insulin sensitivity in our
samples, serum insulin levels were measured by ELISA as well. The Ultra
Sensitive Mouse Insulin ELISA Kit Catalog # 90080 (Crystal Chem) was utilized
with the provided wide range standards.
Measuring Triglyceride Levels
Plasma and liver triglyceride levels were measured using the Serum
Triglyceride Determination Kit Catalog # TR0100 (Sigma-Aldrich, Saint Louis,
MO) with provided reagents. Liver triglyceride concentrations were then
normalized for liver protein concentrations. Liver samples used in the assay were
diluted 40-fold with deionized water.
Measuring Cholesterol Levels
Plasma and liver cholesterol levels were measured using a cholesterol
assay following the Wako Cholesterol E Microtiter Procedure Catalog # 43917501 (Wako Diagnostics, Richmond, VA). Liver cholesterol concentrations were
also normalized to liver protein concentrations. Livers samples used were diluted
five-fold with deionized water.
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Measuring Liver Protein Concentration
Liver protein concentration was measured using Bio-Rad RD DC Protein
Assay dye reagent (Bio-Rad, Hercules, CA) and bovine serum albumin
standards. Absorbance was read at 570 nm. Livers were 2000x diluted for this
purpose.
All assays were read using the ELx800 Absorbance Microplate Reader
(Bio-Tek Instruments, Winooski, VT) and the KC4 Software (Bio-Tek).
Statistical Analyses
Results were analyzed via SPSS 15.0 for Windows (SPSS Inc., Chicago,
IL) using one way Analysis of Variance (ANOVA), two way ANOVA, paired
samples t-test and independent samples t-test. Post-hoc analyses were also
used to compare outcomes using p≤0.05 as a cutoff point for statistical
significance (significant effect). Due to the limited mice available for these
analyses (and the high risk of a type 2 statistical error), a p≤0.1 is noted to
identify comparisons that should be examined more closely in the future. Mean
and standard error of the mean were calculated for each dependent variable.
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Chapter 4
Results
A- Prior to Leptin Pump Study
Preliminary Thrombosis Data
Our thrombosis trial reveals a tendency of lipodystrophic mice to have a
delayed clotting in response to photochemical arterial injury. When compared to
WT littermates, TG mice had significantly longer time to arterial occlusion
(p<0.05) revealing delayed formation of a thrombus (Figure 1). This observation
prompted us to conduct several investigations.
Hematology
Aiming towards finding factors responsible for the altered thrombotic
profile observed in fatless mice, blood cell and platelet counts were obtained
from TG mice and WT controls. The small differences observed were not
statistically significant: blood cell counts (x 109/L) were 8.95 + 0.34 and 8.03 +
0.21 in TG and WT mice, respectively. Platelet counts (x 109/L) were 1.93 + 0.13
in TG mice and 1.53 + 0.21 in WT mice.
Also within the search for underlying factors behind delayed clotting in
fatless mice, a Euglobulin Assay was performed on blood samples obtained from
the same mice mentioned above for the determination of plasma fibrinolytic
activity. As shown in Figure 2, the TG and WT mice had similar trends and
therefore no significant differences in fibrinolysis.
Furthermore, PT and a-PTT were measured in lipodystrophic mice and
wild-type controls and also, no significant differences were observed. PT (sec)
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was 21.75 + 0.63 in the TG group and 20 + 1.53 in the WT group. a-PTT (sec)
was 59.5 + 9.56 and 59.66 + 1.45 in TG and WT mice, respectively.
CBC measures were obtained from TG mice and WT littermates and no
significant differences were found between the two groups, as shown in Table 1.
The above findings, therefore, reveal no significant differences between
WT and TG mice in hematologic and fibrinolytic factors that might explain the
unexpected anti-thrombotic trend of the AZIP-TG mice. We thus proceeded to
leptin administration.
B- Leptin Pump Study
Arterial Thrombosis
The arterial thrombosis data are tabulated in Table 2. A major
complication was encountered during the arterial thrombosis protocol: death of 4
TG mice before occlusion (> 50% of the TG mice). The TG Tx mice that survived
(2 mice), however, did not have the faster clotting that was hypothesized. An
occlusive thrombus was not formed and the experiment was discontinued at 150
minutes. The same non-clotting phenotype was observed in the only TG C
mouse that survived, consistent with the preliminary data of the TG mice. The TG
group had a significantly prolonged time to clotting when compared to the WT
group (p<0.05), as demonstrated in Figure 3. As for WT mice, the difference in
clotting time between the treated and the untreated groups was not significant.
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Body Weights
At baseline, TG mice were significantly heavier than their WT littermates
(p=0.01). Leptin treatment significantly reduced the body weight of both the TG
mice (p<0.005) and the WT mice (p<0.05) (Figure 4).
Figure 5 depicts the percent body weight change in response to
treatment. The values obtained reveal a significant difference in the changes in
body weight between the TG C and the TG Tx groups (p=0.001).
Blood Parameters
Baseline leptin differences between WT mice and TG mice were huge.
WT mice had remarkably higher levels, as leptin levels in TG mice were nearly
undetectable. Figure 6 shows that serum leptin concentration increased with
treatment in both the TG mice (p<0.01) and the WT mice (p<0.05). Control TG
mice had no change in leptin concentration.
Even though the leptin-treated TG mice had lower blood glucose
concentration (88.5 + 30.1) compared to the vehicle-treated TG mice (139.6 +
42.5), this difference (p=0.1) did not reach statistical significance. Values for WT
mice were also not significantly different (C: 126.4 + 6.9; Tx: 106.8 + 7.5).
Figure 7 refers to the change in serum insulin concentration observed in
the WT and TG groups. At baseline, the TG mice had remarkably higher insulin
concentration than the WT mice (p=0.001), as expected. The treatment of TG
mice with leptin resulted in a significant reduction in insulin concentration
(p<0.05). The same effect was seen in the WT mice. No significant changes were
observed in control mice.
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Homeostasis Model Assessment for estimated insulin resistance (81),
HOMA-IR, was computed to analyze the difference in insulin resistance between
the groups. HOMA-IR scores revealed a significantly higher insulin resistance in
the TG C group when compared to the TG Tx group (p=0.01) and either of the
WT groups (p=0.005), as follows: TG C 131.2 + 65.9 > TG Tx 17.4 + 15.1 = WT
C 6.65 + 2.15 = WT Tx 3.39 + 1.68.
Prior to treatment, TG mice had significantly higher levels of triglyceride
in their plasma when compared to WT mice (p=0.005). Plasma triglyceride
concentration did not change significantly after treating the mice with leptin, in
either the TG or WT mice, as shown in Figure 8. However, there was an
unexpected increase in triglyceride in the WT control group.
Plasma cholesterol concentration, as Figure 9 reveals, significantly
dropped in the TG mice upon treatment with leptin (p<0.05). In addition, both the
treatment and control WT mice had a reduction in plasma cholesterol (p<0.05).
The vehicle-treated TG mice did not encounter any significant changes.
Liver Parameters
Protein concentration in livers of the mice was computed for the purpose
of normalizing liver parameters to protein levels.
The liver triglyceride to protein ratio, shown in Figure 10, reveals a
significant difference in triglyceride concentrations between the control TG mice
and the control WT mice (p<0.05), with the former being higher as expected for
“fatless mice”. A trend was evident (p=0.089) for the leptin-treated TG mice to
have a lower liver triglyceride to protein ratio than the vehicle-treated TG mice.
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No significant differences were observed in liver cholesterol to protein
ratios (mg:mg) between groups (TG C 0.0046 + 0.0016 = TG Tx 0.0031 + 0.001
= WT C 0.0041 + 0.001 = WT Tx 0.0042 + 0.001).
Harvested Organ and Tissue Weights
Weights of livers of the mice involved in the study are displayed in
Figure 11 which shows that leptin-treated TG mice had significantly smaller
livers than vehicle-treated TG mice (p<0.05). Moreover, TG-C mice had
significantly larger livers than WT-C mice did (p<0.0001). Livers of the leptintreated TG mice were still significantly heavier than either of those of the WT
mouse groups (p<0.01) i.e. the control WT mice and the treated WT mice. The
differences observed were significantly affected by both the genotypes of the
mice (p<0.0001) and the treatment they received (p<0.05).
Results for the other organs that were weighed are shown in Figure 12:
Organ weights were significantly affected by genotype. However, the difference
in these weights between the control TG mice and the treated TG mice was not
significant. TG mice had heavier spleens, hearts and kidneys than WT mice
(p<0.05), consistent with previous observations. Neither genotype nor treatment
showed a significant effect on differences in lung weights.
Figure 13 graphs the fat pad weights obtained from the mice. Upon
dissection, fat pads from different areas of the mouse body were acquired, i.e.
dorsal, perirenal and gonadal fat. The weight obtained is a combination of all the
above mentioned fat pads weighed together. No visible adipose tissue was found
in the TG mice, whether treated or untreated. The leptin-treated WT mice had

30
significantly less fat following the intervention than their control littermates
(p=0.005).
Figure 14 displays two livers, one obtained from a TG mouse and
another obtained from a WT mouse. The evident difference lies mostly in the size
of the liver where that of the TG mouse is radically larger than that of the WT
mouse (hepatomegaly). A difference in the liver color can also clearly be seen
with the fatty TG mouse liver having a lighter color (due to increased fat
deposition).
Figure 15 shows a dorsal view of 2 skinned mice: a TG and a WT.
Hepatomegaly which is a characteristic property of lipodystrophic mice is evident
in this TG mouse, in addition to the absence of fat pads. The WT mouse, on the
contrary, has a normal dorsal appearance.
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Chapter 5
Discussion
Significant Findings Prior to the Leptin Pump Study
The absence of adipose tissue results in several detrimental effects on
the metabolic and physiological profiles of patients with lipodystrophy, most of
which have been explored. However, even though “better” treatments exist, the
“ideal” or “ultimate” treatment is yet to be found (5-12). Moreover, the
mechanisms underlying the observed alterations need to be more clearly
understood, which may be a key to advancing treatment options. The AZIP/F-1
mouse model, as mentioned previously, shares many characteristics with
lipodystrophic patients and therefore provides an animal model of severe
lipodystrophy on which studies can be performed to unlock the mysteries of this
disease and assist in finding better treatment options (1, 42). It is a mouse model
with a complex phenotype. The metabolic aspects of this phenotype have been
fairly well studied; however, we were curious about other aspects, such as
thrombotic function.
Our arterial thrombosis trial revealed a remarkable and surprising
phenotype in the fatless mice: prolonged time to arterial occlusion/clotting when
exposed to photochemical arterial injury, compared to wild-type littermate mice.
Impaired vascular function has been previously seen in these mice though in a
different way. According to Takemori et al, A-ZIP/F1 lipoatrophic mice are
hypertensive, likely secondary to the lack of perivascular fat tissue and an
upregulation of vascular Ang II type 1 receptors (82). Lamounier-Zepter et al later
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suggested that the high blood pressure observed in these mice may be due to
metabolic-vascular alterations including changes in adrenocortical cells and the
hypercorticosteronemia seen in the mice (83). Thrombosis, however, has not
been examined in these mice. The fatless mice phenotype described above,
therefore, prompted us to investigate about the etiology through examining blood
counts and clotting factors in these mice compared to WT controls. We first
started with the blood cell and platelet counts that were not significantly different
between the TG and WT mice. This meant that there must be a factor beyond
cell and platelet counts that may still be related to blood/thrombotic profiles of the
mice. The next step was determining fibrinolysis that we thought might be altered
in the transgenic mice. However, the euglobulin clot lysis assay that we
performed resulted in similar fibrinolysis trends between the TG and the WT
mice, although the baseline absorbance was different between the groups. We
rendered that to the turbidity that we observed in the plasma samples of the TG
mice, which in turn can be explained by the previously demonstrated
hyperlipidemia in the blood of these mice (42, 44, 45). We then proceeded to
obtaining CBC’s and PT tests from TG mice and WT controls where again,
differences between the two groups were not evident. Our last step in evaluating
hematologic and fibrinolytic differences was measuring a-PTT which also was not
different in the TG mice when compared to their WT littermates. Our conclusion
was that the delayed clotting observed in these mice must be the result of a
mechanism or an anomaly that is not related to hematologic and fibrinolytic
factors but rather to a different characteristic of lipodystrophic mice.
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Arterial thrombosis trials performed in the past have shown a positive
correlation between leptin and blood clotting, i.e. in other words, leptin has been
shown to promote platelet aggregation and therefore blood clotting in humans
(70, 71) as well as in mice (74-77). Leptin is very low or undetectable in AZIP-TG
mice (42) and at the same time our mice had normal blood counts and clotting
factor profiles as previously stated. These findings combined led to the
hypothesis that the absence of leptin may be behind the altered thrombotic
phenotype seen in our lipodystrophic mice. By providing these mice with leptin,
we could test the above hypothesis and examine the metabolic effects of leptin
administration specifically on the FVB/B6 lipodystrophic mice. We therefore
provided our four mouse groups with leptin or control solutions exogenously and
compared the parameters and changes of interest at different time intervals.
Arterial Thrombosis
Although we had a minimal number of

successful thrombotic

experiments to rigorously test our hypothesis, our data do not support an effect of
leptin on thrombosis in the A-ZIP mice. Regardless of whether or not they were
receiving leptin, we observed an extremely delayed occlusion time after
photochemical injury to the carotid artery of A-ZIP TG mice. We have not been
able to attribute this surprising alteration to enhanced fibrinolysis, deficient
clotting factors, or abnormal blood/platelet counts. Although we regret that we
were unable to obtain an adequate number of animals to carefully test our
hypothesis, we feel relatively confident that leptin does not “rescue” the altered
thrombotic phenotype of the A-ZIP mice. Our poor success in attaining the
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arterial thrombosis endpoint in these studies (with mortality of more than half of
our TG mice during the procedure), is a function of the difficulty in delivering
anesthesia to these mice. Maintaining their depth of anesthesia at an adequate
level (without overdose) is very difficult, as previously mentioned in studies of the
AZIP-TG mouse (42).
Body and Organ/Tissue Weights
TG mice weighing more than WT mice was not surprising. This was seen
previously (42) and can be explained by organ enlargement that fatless mice
encounter as they mature, especially hepatomegaly (42, 44, 45). As expected,
treatment with leptin led to a decrease in body weight in both the TG and WT
mice. This finding is not surprising since leptin is known to control weight via
controlling energy intake and metabolism (15, 16). The reduction in body weight
may further be attributed to increasing energy expenditure in the WT mice though
this may be unlikely in the TG mice since leptin therapy has been associated with
a reduction in energy expenditure in lipodystrophic subjects (5, 10).
The trends of organ and tissue weights were also as we had expected.
Livers of TG mice were significantly larger than those of WT mice, which has
been previously shown (42, 44, 45). This difference in size is attributed to several
factors, mainly the fact that the liver in lipodystrophic animals is acting as a
storage depot that also stores what would normally be stored in adipose cells, i.e.
triglycerides (42), which leads to the previously proven hepatic steatosis in
lipodystrophic mice (34-37, 42, 84). Moreover, the inflammatory state that is seen
in these animals (51) may be playing a role in contributing to organomegaly,
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mainly hepatomegaly, knowing that hepatic steatosis and inflammation have
generally been shown to be associated (84). The livers of leptin-treated TG mice,
on the other hand, were significantly smaller than those of the control TG mice, a
result that was also predictable and supported by the literature (42, 44, 45).
Leptin administration clearly ameliorated the hepatomegaly through enhancing
metabolism. It attenuated the steatotic state, an effect that has been seen in both
lipodystrophic patients (11) and mice (56). This may partly explain the described
alterations in body weight observed in our TG mice.
Spleens, hearts and kidneys were heavier in TG mice than in WT mice.
This is consistent with previous findings that reported organomegaly in
lipodystrophic mice (42, 44, 45). These organs were not lighter in leptin-treated
TG mice when compared to vehicle-treated TG mice. This may imply that some
of the anomalies caused by lipodystrophy are irreversible.
The most exciting part of the dissections was the extensive search for fat
pads. None were found in the TG mice. This coincides with previous findings (42,
49) and explains most of the physiological and metabolic abnormalities.
Importantly, leptin-treated WT mice had less fat than control WT mice did. This
implies that leptin treatment was effective and that these WT mice were “leptin
sensitive”.
Blood and Liver Parameters
At baseline, TG mice had very low levels of leptin (< 0.5 ng/ml), i.e. below
normal physiological levels (85). This was anticipated due to the lack of fat in TG
mice and therefore a lack of this adipocyte-derived hormone. Consistent with
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this, serum leptin concentration has been observed to be directly proportional to
fat mass (5). As expected, the WT mice had significantly higher leptin
concentrations at baseline, which were in the normal physiologic range. Upon
treatment, serum leptin levels in the leptin-treated TG mice increased robustly
(almost 7-fold), while vehicle-treated TG littermates encountered no change in
leptin concentration. These findings demonstrate that our leptin treatment (via
osmotic pump) of TG mice effectively increased the serum leptin concentration
into a normal physiologic range.
Blood glucose (BG) levels of untreated TG mice were higher than those of
treated mice where the former met the criteria for hyperglycemia and the latter
fell within the normoglycemia range; however, these differences were not
significant. This is likely due to the variability of the measure, the limited number
of mice, and the modest elevation of glucose in this relatively young cohort. In
future studies, it will be helpful to obtain BG levels at several time points to more
accurately observe the effect of treatment on the mice. This was not done in this
study in order to avoid excessive blood withdrawal from the mice and therefore
additional stress.
TG mice, which were expected to be diabetic/ insulin resistant at the time
of the blood draw, did have significantly more circulating insulin than did their WT
controls, at baseline. In addition, compared to the TG control-treated mice (which
became worse during the intervention period), the TG leptin-treated mice had
significantly reduced fasting insulin concentration. This is consistent with
previous findings where insulin resistance became progressively worse from 4
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weeks of age to 10 weeks of age in the Azip fatless mice (49), and where leptin
enhanced insulin sensitivity in fatless mice (55-57). We also observed a
reduction in insulin concentration in leptin-treated WT mice suggesting that a
deficit of leptin at baseline was not required for a decrease in fasting insulin
during leptin treatment.
HOMA-IR scores confirmed that the TG C group was extremely insulin
resistant and that this effect was ameliorated following leptin treatment. This is
also consistent with the known insulin resistant phenotype of lipodystrophic mice
(44, 45) that is improved with leptin therapy (56).
High circulating levels of lipids in the blood are expected in fatless mice
that lack the normal mammalian fat storage depot (42). This was confirmed in our
study when comparing these mice to controls at baseline. Triglyceride levels
obtained from plasma samples did not change significantly in the TG mice. They
seemed to remain almost the same upon treatment, which might imply that
treatment at least prevented further increase in triglyceride concentration in the
blood. The only significant change that was seen is an increase in triglyceride
levels in the untreated WT mice. This may be a normal trend related to age. As
for liver triglyceride measures, as expected, levels were higher in TG mice than
in WT mice (vehicle-treated). This has been previously documented (49) as
AZIP-TG mice are known to develop hepatic steatosis (42). Moreover, the leptintreated TG group had lower levels than did the vehicle group, which is supported
by previous studies both in humans (5, 9) and in mice (56). These results are
explained by 1) the fact that the liver in the TG mice acts as the major triglyceride
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storage depot in the absence of adipose cells, causing triglyceride accumulation
and hepatic steatosis; and 2) the fact that leptin improves triglyceride metabolism
and thereby reduces hepatic triglyceride accumulation.
In both plasma and liver, there were no significant differences in
cholesterol levels of TG versus WT mice. This was surprising as previous studies
have reported hyperlipidemia in lipodystrophic mice (42, 44, 45). What was
expected, however, is the reduction in plasma cholesterol concentration in the
leptin-treated TG mice. This coincides with previous suggestions that leptin
improves lipid metabolism in both lipodystrophic humans (11, 12, 86) and mice
(55, 56).
Of interest, the A-ZIP phenotype has been demonstrated to be affected
by genetic background. For example, A-ZIP mice on the FVB background have
higher circulating triglyceride and fatty acid levels and more hyperglycemia than
those on the B6 background according to Colombo et al in 2003 (43). This may
explain some of the unexpected findings listed above.
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Chapter 6
Conclusion
The United States has been facing a remarkable increase in obesity over
the last two decades, associated with several disorders (87-92). Nonalcoholic
fatty liver disease is rapidly spreading mainly in the form of hepatic steatosis
which in turn is a known component of obesity and the metabolic syndrome along
with insulin resistance and hyperlipidemia (93). Insulin resistance and
dyslipidemia can be caused by either excessive adiposity or lack of adipose
tissue (94). Lipodystrophy, therefore, carries many of the same characteristics as
more common metabolic diseases. This disease is being actively researched and
effective mouse models have been produced, with the Azip-transgenic model
being very similar in physiology and metabolism to some lipodystrophic patients
(1, 42). Ongoing and future studies using these models should help explore the
vague aspects of lipodystrophy and provide more effective treatment options for
lipodystrophic patients.
Adipose tissue serves as an endocrine organ through secreting several
bioactive compounds (adipokines) whose dysregulation is thought to contribute
to insulin resistance and metabolic disease (94). Leptin, a major adipokine, has
an essential role in energy homeostasis (5). Low leptin levels appear to be a
characteristic abnormality in lipodystrophic patients that can serve as an effective
therapy for reducing their metabolic disease. However, as previously introduced,
there are many forms of lipodystrophy, so a clear mechanistic understanding of
each disease will lead to the most effective treatment strategies.
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In addition, the administration of adipokines other than leptin might be a
promising future research option since these adipokines may turn out to be key
players in many of the metabolic and physiological aspects of lipodystrophy,
obesity and/or the metabolic syndrome.
Aside from the metabolic and physiological characteristics, the transgene
possessed by the fatless mice may be leading to an altered thrombotic function
via mechanisms that are unrelated to the lipodystrophy or metabolic disturbances
of this model. Therefore, adipose tissue transplantation in the A-ZIP
lipodystrophic mice may help determine whether it is truly the absence of adipose
tissue that induces the observed thrombotic alterations or whether the effect is a
by-product of the transgenic strategy. Additionally, transplanting adipose tissue
that lacks leptin may further aid in understanding and dissociating these factors.
In the future, in a study like ours, a larger sample size and a longer
duration would likely produce more significant outcomes with a reduced
variability. These study-design improvements combined with the above research
suggestions may help solve unanswered questions about the lipodystrophies and
possibly find treatment targets not only for these disorders, but also for other
chronic metabolic conditions such as diabetes.
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Figure 1
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Figure 1- Formation of Occlusive Thrombus in Wild-type (WT) and
Transgenic Fatless (TG) FVB/B6 Mice. TG mice have a delayed time
to arterial occlusion, compared to WT mice.
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Figure 2
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Figure 2- Euglobulin Clot Formation and Lysis in FVB/B6 Mice.
Similar trends in fibrinolysis are observed in TG and WT mice.
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Figure 3
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Figure 3- Time to Formation of Occlusive Thrombus per Group. TG
mice have a prolonged time to arterial occlusion, compared to WT mice.
When comparing TG mice that survived, TG C (n=1) and TG Tx (n=2)
are not different.
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Figure 4
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Figure 4- Day by Day Body Weights per Group. TG mice are
heavier than WT mice at baseline. Following the intervention, both TG
and WT leptin-treated mice lost weight, comparing pre-treatment to
post-treatment weights.
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Figure 5
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Figure 5- Percent Body Weight Change per Group. TG C mice
continued to gain weight as they mature while leptin-treated mice (TG
and WT) lost weight.
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Figure 6
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Figure 6- Change in Mean Serum [Leptin] per Group. Baseline
serum leptin levels are higher in WT mice where TG mice have nearly
undetectable levels. Both the TG and the WT leptin-treated groups
had an increase in circulating leptin.
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Figure 7
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Figure 7- Change in Mean Serum [Insulin] per Group. Baseline
serum insulin levels are higher in TG mice compared to WT mice.
Both the TG and the WT leptin-treated groups had a reduction in
insulin levels.
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Figure 8
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Figure 8- Change in Mean Plasma [Triglyceride] per Group.
Baseline plasma triglyceride levels are higher in TG mice compared to
WT mice. No significant reductions were observed upon treatment
with leptin.
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Figure 9
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Figure 9- Change in Mean Plasma [Cholesterol] per Group.
A significant reduction was observed in all groups except in the
TG C group.
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Figure 10- Mean Liver [Triglyceride:Protein] per Group. TG C
mice have higher levels of liver triglyceride than WT C mice.
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Figure 11

Liver Wt as % TBWt

10

a

8

b

6
c

c

4
2
0
TG C

TG Tx

WT C

WT Tx

Bars with different superscripts are significantly different from each other
(p <0.05)
Figure 11- Mean Liver Weight as % Total Body Weight per Group.
Livers of TG mice are heavier than those of WT mice. Livers of leptintreated TG mice are lighter than those of vehicle-treated TG mice.
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Figure 12- Mean Organ/Tissue Weights as % Total Body
Weight per Group. TG mice have larger organs compared to
WT mice. No significant effect of treatment is seen.
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Figure 13
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Figure 13- Total Adipose Tissue Weight as % Total Body Weight per
Group. Both groups of TG mice lack visible adipose tissue. WT Tx mice
have less fat than WT C mice.
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Figure 14

Figure 14- Mouse Livers Following Dissection. A TG mouse liver
with hepatomegaly and steatosis (left) vs a healthy WT littermate liver
(right).
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Figure 15
(a)

(b)

Figure 15- Dorsal View of Skinned Mice with Intact Organs and
Tissues. (a) The TG mouse has a large liver occupying most of the
abdominal cavity and lacks visible fat pads. (b) The WT mouse has a
normal dorsal view with the absence of organomegaly and the
presence of fat pads.
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Table 1: Complete Blood Counts (CBC) in Wild-Type Vs
Transgenic FVB/B6 Mice (Mean ±SEM)
Blood Parameter

Genotype
Wild-type

Transgenic

492.33 + 65.9

567.25 + 55.1

WBC (103/ul)

4.87 + 0.67

4.825 + 0.85

RBC (106/ul)

9.77 + 0.44

9.70 + 0.66

MCV (fl)

43.93 + 0.88

46.08 + 0.27

RDW

18.67 + 0.59

17.9 + 0.34

MCHC (g/dl)

35.2 + 0.75

34.78 + 0.28

MCH (pg)

15.4 + 0.10

16 + 0.04

MPV (fl)

6.33 + 0.07

6.4 + 0.04

HGB (g/dl)

15.07 + 0.73

15.53 + 1.08

% HCT

42.97 + 2.63

44.73 + 3.24

% Lym

81.33 + 3.37

78.35 + 2.29

% Mon

6.4 + 1.07

6.6 + 0.31

% Gra

12.27 + 2.44

15.05 + 1.99

Plt (103/ul)
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Table 2: Leptin Pump Thrombosis Data: Time to Occlusion
Mouse Group

Time to Occlusion (m)

Status

TG C

48

Expired

TG C

150+

Discontinued

TG C

60

Expired

TG Tx

150+

Discontinued

TG Tx

87

Expired

TG Tx

150+

Discontinued

TG Tx

19

Expired

WT C

53

Completed

WT C

17

Completed

WT C

47

Completed

WT C

52

Completed

WT C

80

Completed

WT Tx

29

Completed

WT Tx

31

Completed

WT Tx

46

Completed

WT Tx

59

Completed
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Lipodystrophy caused by fat deficiency contributes to metabolic disease
for which several treatment modalities have been implemented, with leptin
therapy being the most effective to date. In addition to playing a role in energy
homeostasis and metabolism, leptin was also shown to play a pro-thrombotic role
in mice. This role was not examined in fatless mice, neither was thrombosis
measured. The AZIP/F-1 (FVB) lipodystrophic mouse appeared to have a
prolonged arterial occlusion time (p<0.05) in a trial done in our lab, with clotting
factors being normal. The present study was designed to observe the thrombotic
and metabolic characteristics of fatless mice and examine the effect of leptin
therapy on these traits. 16 FVB/B6 mice were produced in-house for the study, to
receive recombinant mouse leptin or saline via osmotic pumps over 12 days.
Transgenic (TG) mice were randomly divided into two groups: Treatment (Tx,
n=4) and control (C, n=3); and their wild-type (WT) littermates were similarly
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divided into Tx (n=4) and C (n=5). TG mice had a prolonged time to formation of
occlusive thrombus compared to WT mice (p<0.05). Leptin treatment did not
have an effect on arterial thrombosis in our mice. At baseline/control, TG mice
were heavier than WT mice (p<0.05), had larger livers (p<0.0001), larger kidneys
(p=0.01), higher serum insulin (p<0.01), higher plasma and liver triglyceride
(p<0.01 and p<0.05, respectively) and less leptin (p<0.0001). TG-Tx mice
decreased in weight (p<0.05) and had smaller livers than those of TG-C mice
(p<0.05) while having higher levels of circulating leptin (p=0.01) and reduced
levels of serum insulin (p<0.05) and plasma cholesterol (p<0.05). TG C mice had
higher HOMA-IR scores (p<0.05) than all other groups verifying insulin resistance
that is ameliorated by leptin therapy. These findings confirm the hepatomegaly,
hyperinsulinemia/ insulin resistance and hyperlipidemia seen in fatless mice and
the effectiveness of leptin therapy while also suggesting that lipodystrophy, at
least in the AZIP/F-1 mouse, is associated with delayed thrombosis independent
of the lack of leptin. Lipodystrophic mice remain a useful model to study current
epidemic metabolic disorders.
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